Vernal Point Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Vernal Point Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,090	Closed	-$339K	–	23
2025 Q2	$339K	Hold	4,090	–	–	0.2%	18
2025 Q1	$332K	Hold	4,090	–	–	0.22%	18
2024 Q4	$368K	Hold	4,090	–	–	0.25%	18
2024 Q3	$404K	Sell	4,090 -1,711	-29%	-$168K	0.31%	19
2024 Q2	$538K	Hold	5,801	–	–	0.38%	20
2024 Q1	$550K	Hold	5,801	–	–	0.47%	22
2023 Q4	$518K	Buy	+5,801	New	+$431K	0.54%	17

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Vernal Point Advisors's XBI Position: Q3 2025 in Review

Vernal Point Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2025, closing a stake of 4,090 shares — an estimated $339K sold.

Vernal Point Advisors first reported a position in XBI in Q4 2023 and held it in 7 quarters. The position peaked at $550K in Q1 2024. 656 funds tracked by Wall St. Rank hold XBI as of Q3 2025.

Vernal Point Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2025 after selling out during the quarter.
Vernal Point Advisors sold 4,090 State Street SPDR S&P Biotech ETF shares in Q3 2025, an estimated $339K.
Vernal Point Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and held it in 7 quarters.
Vernal Point Advisors's State Street SPDR S&P Biotech ETF position peaked at $550K in Q1 2024.
656 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2025.

Based on Vernal Point Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.